Specifications
Immunogen
Porcine alveolar macrophages
Applications
Application Notes
Flow Cyt: 1/10 - 1/20
Target
Alternative Names
SIRPA; swc3; PTPNS1; tyrosine-protein phosphatase non-receptor type substrate 1; swine workshop cluster 3 antigen; protein tyrosine phosphatase, non-receptor type substrate 1
Product Background
Antigen Description
Clone CM2I8 was originally clustered as SWC3 at the Third International Swine Cluster of Differentiation Workshop. CD172a is expressed on monocyte derived dendritic cells (MoDCs) also conventional (cDCs), plasmacytoid (pDCs) DCs and blood DCs. Clone CM2I8 immunoprecipitated a single band of ~90-110kDa from preparations of biotinylated alveolar macrophages, a result confirmed by Western blotting analysis of alveolar macrophage lysates under non reducing conditions.
Pathway
Antigen processing and presentation; DAP12 interactions; DAP12 signaling; Graft-versus-host disease; Immune System; Innate Immune System; Natural killer cell mediated cytotoxicity
Citations
Publication ()
Have you cited DCABY-350 in a publication?
Let us know and earn a reward for your research.
Anti-CD47 monoclonal antibody therapy reduces ischemia-reperfusion injury of renal allografts in a porcine model of donation after cardiac death
Xu M, Wang X, Banan B, Chirumbole DL, Garcia-Aroz S, Balakrishnan A, Nayak DK, Zhang Z, Jia J, Upadhya GA, Gaut JP, Hiebsch R, Manning PT, Wu N, Lin Y, Chapman WC.
Applications: WB
Reactive species: Pig
"Abstract: We investigated whether blockade of the CD47 signaling pathway could reduce ischemia-reperfusion injury (IRI) of renal allografts donated after cardiac death (DCD) in a porcine animal model of transplantation. Renal allografts were subjected to 30 min of warm ischemia, 3.5 hours of cold ischemia and then perfused with a humanized anti-CD47 monoclonal antibody (CD47mAb) in the treatment group or HTK solution in the control group (n=4/group). The animals were euthanized 5 days after transplantation. At the time of reperfusion, indocyanine green-based in vivo imaging showed that CD47mAb-treated organs had greater and more uniform reperfusion. On post-transplant days 3–5, the treatment group had lower values compared to the control for creatinine and blood urea nitrogen. Histological examination of allograft tissues showed a significant decrease of acute tubular injury in the CD47mAb-treated group compared to control. Compared to the control group, CD47mAb treatment significantly decreased genes expression related to oxidative stress (sod-1, gpx-1, and txn), the inflammatory response (il-2, il-6, inf-g and tgf-b), as well as reduced protein levels of BAX, Caspase-3, MMP2, and MMP9. These data demonstrate that CD47mAb blockade decreases IRI and subsequent tissue injury in DCD renal allografts in a large animal transplant model."
Article snippet: To demonstrate the specificity of CD47mAb binding, the humanized CD47mAb was used as primary antibody to perform Western blots. In addition, an anti-SIRP-alpha (DCABY-350, Creative Diagnostics) and an anti-TSP-1 (MA5-13398) were also used. 
Figure 1. Western blots there was no overlap of the binding sites between the humanized CD47mAb and the SIRP-alpha or TSP-1 in the pig kidney and liver.
COA
Loading ......
